Alkermes plc (8AK) - Total Liabilities

Latest as of March 2026: €2.51 Billion EUR ≈ $2.93 Billion USD

Based on the latest financial reports, Alkermes plc (8AK) has total liabilities worth €2.51 Billion EUR (≈ $2.93 Billion USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Alkermes plc net asset momentum to track the company's year-over-year net asset growth rate.

Alkermes plc - Total Liabilities Trend (2013–2025)

This chart illustrates how Alkermes plc's total liabilities have evolved over time, based on quarterly financial data. See Alkermes plc (8AK) free cash flow to measure how efficiently the company converts operating cash flow to free cash.

Alkermes plc Competitors by Total Liabilities

The table below lists competitors of Alkermes plc ranked by their total liabilities.

Company Country Total Liabilities
Rigetti Computing Inc
NASDAQ:RGTI
USA $67.09 Million
Sinomine Resource Exploration Co Ltd
SHE:002738
China CN¥5.88 Billion
Bharat Dynamics Limited
NSE:BDL
India Rs88.51 Billion
Impack Pratama Industri Tbk
JK:IMPC
Indonesia Rp2.13 Trillion
Colliers International Group Inc Bats
TO:CIGI
Canada CA$4.12 Billion
Scout24 AG
XETRA:G24
Germany €737.38 Million
Clal Insurance Enterprises Holdings Ltd
TA:CLIS
Israel ILA177.44 Billion
Construction Partners Inc
NASDAQ:ROAD
USA $2.46 Billion

Liability Composition Analysis (2013–2025)

This chart breaks down Alkermes plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Alkermes plc (8AK) total market value.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 2.27 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 1.43 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.59 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Alkermes plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Alkermes plc (2013–2025)

The table below shows the annual total liabilities of Alkermes plc from 2013 to 2025.

Year Total Liabilities Change
2025-12-31 €667.70 Million
≈ $780.61 Million
+13.06%
2024-12-31 €590.59 Million
≈ $690.46 Million
-36.74%
2023-12-31 €933.54 Million
≈ $1.09 Billion
+1.45%
2022-12-31 €920.23 Million
≈ $1.08 Billion
+0.91%
2021-12-31 €911.90 Million
≈ $1.07 Billion
+39.49%
2018-12-31 €653.72 Million
≈ $764.27 Million
+9.98%
2017-12-31 €594.42 Million
≈ $694.94 Million
+14.99%
2016-12-31 €516.94 Million
≈ $604.36 Million
-4.53%
2015-12-31 €541.47 Million
≈ $633.03 Million
+3.69%
2014-12-31 €522.22 Million
≈ $610.53 Million
+1.92%
2013-12-31 €512.40 Million
≈ $599.05 Million
--

About Alkermes plc

F:8AK Germany Drug Manufacturers - Specialty & Generic
Market Cap
$8.15 Billion
€6.97 Billion EUR
Market Cap Rank
#3555 Global
#660 in Germany
Share Price
€41.83
Change (1 day)
-1.83%
52-Week Range
€23.40 - €48.19
All Time High
€48.19
About

Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and … Read more